Clinical Trial Update: Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts [NA]

View source ↗

Summary

A completed clinical trial evaluated combining ipilimumab with lymphodepletion, adoptive cell transfer, and high-dose interleukin-2 in metastatic melanoma; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Proleukin (aldesleukin)
• ipilimumab (ipilimumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Melanoma | NA | Status: COMPLETED | Results posted: 2017-05-02